表皮生长因子受体突变非小细胞肺癌耐药机制的研究进展

目前，肺癌的发病率及病死率仍居全球各类癌症的首位。肺癌确诊时常为中晚期，放化疗疗效不理想，术后复发与转移率较高。靶向治疗，如表皮生长因子受体(epidermal growth factor receptor,EGFR)酪氨酸激酶抑制剂(tyrosine kinase inhibitors,TKIs)的应用，显著提高了伴EGFR突变的中晚期非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的临床疗效。但由于耐药的发生，NSCLC患者预后仍然欠佳。本文对EGFR突变的NSCLC患者对TKIs耐药机制的研究进展作一综述，以期为临床探索新的解决策略提供依据。

Research progress of drug resistance mechanism for non-small cell lung cancer patients with epidermal growth factor receptor mutations

At present, the morbidity and mortality of lung cancer still rank first among all kinds of cancers in the world. Lung cancer diagnosis is often in the intermediate and terminal stage, and its radiotherapy and chemotherapy are not effective, with high postoperative recurrence and metastasis rate. Targeted therapies, such as epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs), have significantly improved clinical outcomes of patients with advanced non-small cell lung cancer (NSCLC) complicated with EGFR mutation. However, the prognosis is still poor due to the occurrence of drug resistance. This article reviews the research progress of TKIs resistance mechanism in NSCLC patients with EGFR mutation, so as to provide reference for clinical exploration of new treatment strategies.